Article Text

PDF
Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment
  1. Gagandeep Singh1,
  2. Jeremy H Rees2,
  3. Josemir W Sander2
  1. 1Department of Neurology, Dayanand Medical College, Ludhiana, India
  2. 2UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
  1. Correspondence to:
 Professor Ley Sander
 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; lsander{at}ion.ucl.ac.uk

Abstract

There are few data available on the causes and mechanistic basis, outcome and treatment of seizures and epilepsy in people with systemic cancer. Seizures and epilepsy in people with cancers other than primary brain tumours are reviewed here. Articles published in English, which discussed the neurological manifestations and complications of cancer and its treatment, were searched and information on the frequency, aetiology, and course of seizures and epilepsy was extracted. The frequency, aetiology and outcome of seizure disorders in patients with cancer differ from those in the general population. Intracranial metastasis, cancer drugs and metabolic disturbances are the most common causes. Infections, cerebrovascular complications of systemic cancer and paraneoplastic disorders are among the rarer causes of seizures in patients with neoplasms. Several drugs used in the treatment of cancer, or complications arising from their use, can trigger seizures through varied mechanisms. Most drug-induced seizures are provoked and do not require long-term treatment with antiepileptic drugs.

  • BMT, bone marrow transplantation
  • CNS, central nervous system
  • EEG, electroencephalograph
  • MRI, magnetic resonance imaging
  • 5-FU, 5-fluorouracil
  • MUD, matched unrelated donor

Statistics from Altmetric.com

Footnotes

  • Funding: A Commonwealth Fellowship supported GS.

  • Competing interests: GS has received travel support and research grants from Janssen Cilag, Sanofi-Aventis and Pfizer. JHR has received research support from UCB Pharma. JWS has received honoraria, research and travel grants from Novartis, Pfizer, UCB, Eisai, Schwarz Pharma, Janssen-Cilag, Sanofi-Aventis and GSK.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.